MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood-2011-07-362475

Медицинская библиотека · Blood · 2011

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Fehniger Todd A, Larson Sarah, Trinkaus Kathryn, Siegel Marilyn J, Cashen Amanda F, Blum Kristie A, Fenske Timothy S, Hurd David D, Goy Andre, Schneider Stephanie E, Keppel Catherine R, Wagner-Johnston Nina D, Carson Kenneth R, Bartlett Nancy L

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel/ref cHL patients was evaluated at a dose of 25 mg/d on days 1-21 of a 28-day cycle. Patients remained on lenalidomide until disease progression or an unacceptable adverse event (AE) occurred. Thirty-eight cHL patients were enrolled with a median of 4 (range, 2-9) prior therapies; 87% had undergone prior stem cell transplantation and 55% of patients did not respond to their last prior therapy. Of 36 evaluable patients, responses were 1 complete remission (CR), 6 partial remissions (PRs), and 5 patients with stable disease (SD) for ≥ 6 months resulting in an International Working Committee (IWC) objective overall response rate (ORR) of 19% and a cytostatic ORR of 33%. Decreased chemokine (CCL17 and CCL22) plasma levels at 2 weeks were associated with a subsequent response. The treatment was well tolerated, and the most common grade 3/4 AEs were neutropenia (47%), anemia (29%), and thrombocytopenia (18%). Four patients discontinued lenalidomide because of rash, elevated transaminases/bilirubin, and cytopenias. We provide preliminary evidence of lenalidomide's activity in patients with rel/ref cHL, and therefore exploration of lenalidomide in combination with other active agents is warranted. This trial is registered at www.ClinicalTrials.gov as NCT00540007.

Для цитирования: Fehniger Todd A, Larson Sarah, Trinkaus Kathryn, Siegel Marilyn J, Cashen Amanda F, Blum Kristie A, Fenske Timothy S, Hurd David D, Goy Andre, Schneider Stephanie E, Keppel Catherine R, Wagner-Johnston Nina D, Carson Kenneth R, Bartlett Nancy L. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.. Blood. 2011. DOI: 10.1182/blood-2011-07-362475.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.